Genmab AS (Genmab) develops human antibody therapies for the potential treatment of cancer and other diseases. It focuses on developing antibody therapies by using technologies such as HexaBody, DuoBody, DuoHexaBody and HexElect.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Genmab conducts research to develop antibody products and pipelines for the treatment of cancer and other diseases. The company employs its proprietary technology platforms such as DuoBody, HexaBody and HexElect. DuoBody is used in the discovery and development of bispecific antibodies. Bispecific antibodies generated using the DuoBody platform possess the capability to improve antibody therapy in cancer, autoimmune, infectious and central nervous system diseases. HexaBody is an antibody platform that facilitates the development of potent therapies by including antibody hexamer formation. DuoHexaBody combines DuoBody and HexaBody and creates bispecific antibodies with target-mediated hexamerization. HexElect combines two HexaBody molecules to introduce selectivity while maximizing therapeutic potency. Genmab also uses or licenses technologies such as UltiMab transgenic mouse technology; OmniAb transgenic mouse and rat platforms, and antibody-drug conjugates to increase the potency of its antibody therapies. The company operates an R&D center in Utrecht, the Netherlands. The company has also expanded its research capabilities through collaborations with companies like AbbVie, BioNTech, J&J, and Novo Nordisk, focusing on the development of bispecific antibodies and other innovative therapies. Its R&D efforts are aimed at transforming the lives of patients with cancer and other serious diseases through groundbreaking medicines. In FY2024, the company spent USD9,748 million on its research and development, which, as a percentage of revenue, stood at 45.2%.